Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Corona RemediesNSE:CORONA -1.37%19 Return-on-Tangible-Asset is 25.52% as of Jun. 2026, which is 41% above its 10-year median of 18.05. GuruFocus rates NSE:CORONA with a GF Score™ of 19/100. The stock has 5 warning signs investors should review. Among 1,008 Drug Manufacturers companies, Corona Remedies ranks better than 91.57% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Corona Remedies's annualizedNet Income for the quarter that ended in Jun. 2026 was ₹2,404 Mil. Corona Remedies's average total tangible assets for the quarter that ended in Jun. 2026 was ₹9,423 Mil. Therefore, Corona Remedies's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2026 was 25.52%.
The historical rank and industry rank for Corona Remedies's Return-on-Tangible-Asset or its related term are showing as below:
NSE:CORONA'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 14.29 Med: 18.05 Max: 21.77
Current: 17.28
During the past 4 years, Corona Remedies's highest Return-on-Tangible-Asset was 21.77%. The lowest was 14.29%. And the median was 18.05%.
NSE:CORONA's Return-on-Tangible-Asset is ranked better than 91.57% of 1008
companies
in the Drug Manufacturers industry
Industry Median: 2.795
vs NSE:CORONA: 17.28
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Corona Remedies Return-on-Tangible-Asset Related Terms
Corona Remedies Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Corona Remedies's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:CORONA vs LLY, JNJ, ABBV: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - General subindustry, Corona Remedies's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Corona Remedies Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Corona Remedies's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Corona Remedies's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2026) net income data.
What does a Return-on-Tangible-Asset of 25.52% mean?
Corona Remedies (NSE:CORONA) has a Return-on-Tangible-Asset of 25.52% as of Jun. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Corona Remedies and its competitors. This is 41% above median its historical median of 18.05. Over the past decade, Corona Remedies' Return-on-Tangible-Asset has ranged from 14.29 to 21.77. According to the industry distribution chart, Corona Remedies ranks #85 out of 1008 companies in the Drug Manufacturers industry, placing it in the top 8.4%.
Is Corona Remedies' Return-on-Tangible-Asset too high?
Corona Remedies' current Return-on-Tangible-Asset of 25.52% is 41% above median its 10-year median of 18.05. Over the past 10 years, this metric has ranged from a low of 14.29 to a high of 21.77. The Drug Manufacturers industry median Return-on-Tangible-Asset is 2.80. Corona Remedies' value of 25.52% is 813.1% above this industry median. Based on the distribution chart, Corona Remedies ranks #85 out of 1008 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Corona Remedies has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Corona Remedies' Return-on-Tangible-Asset compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Corona Remedies ranks #85 out of 1008 companies for Return-on-Tangible-Asset. This places Corona Remedies in the top 8% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 2.80. Corona Remedies' value of 25.52% is 813.1% above this benchmark. Historically, Corona Remedies' own Return-on-Tangible-Asset has ranged from 14.29 to 21.77 over the past decade. While the company's 10-year median is 18.05 vs. the industry median of 2.80, Corona Remedies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 2.80, based on 1,008 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Corona Remedies's current Return-on-Tangible-Asset of 25.52% is 813.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Corona Remedies and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Corona Remedies's current Return-on-Tangible-Asset is 25.52%, which is 41% above median its own 10-year median of 18.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corona Remedies stock overvalued right now?
Corona Remedies (NSE:CORONA) has a current Return-on-Tangible-Asset of 25.52%. The current Return-on-Tangible-Asset is 25.52%, which is 41% above median its 10-year median of 18.05 and 813.1% above the Drug Manufacturers industry median of 2.80. Corona Remedies' overall GF Score™ is 19/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Corona Remedies (NSE:CORONA), the current Return-on-Tangible-Asset is 25.52% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Corona Remedies Ltd is mainly engaged in the business of manufacturing, trading and marketing of Pharmaceutical products. It is engaged in developing, manufacturing and marketing products in women's healthcare, cardio-diabetes, pain management, urology and other segments, such as Vitamin Minerals and Nutrients(VMN), gastrointestinal and respiratory therapies. The company's brands are B-29, myoril, Tricium, Cortel, and Obimet. The Company has only one reportable business segment i.e. Pharmaceuticals. The company has presence in India as well as Outside India. The company generates majority of revenue from India.
19GF Score
Get the complete analysis for NSE:CORONA
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:CORONA has been successfully added to your 
